NCT01113047View on ClinicalTrials.gov

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

PHASE3CompletedINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2010

Conditions
Essential Hypertension
Interventions
DRUG

Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ

Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg

Trial Locations (1)

Unknown

Investigative Site, Pirna

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY